HomeCancer BiologyCancer TypesBreast Cancer: Biology, Types, Diagnosis, and Treatment

Breast Cancer: Biology, Types, Diagnosis, and Treatment

- Advertisement -

Breast cancer is a common and biologically complex disease that develops from uncontrolled cell growth in breast tissue, most often in the ducts or lobules. It represents a major global health burden and remains one of the leading causes of cancer-related death among women.

At the cellular level, breast cancer is highly heterogeneous, with tumors differing in their molecular characteristics, behavior, and response to therapy.

This article explores the biological basis of breast cancer, its classification, diagnosis, and therapeutic strategies, providing a clear framework that links fundamental cancer biology to clinical practice.

1. Breast Anatomy and Cellular Origin of Breast Cancer

The human breast is a specialized glandular organ composed of three main components: lobules, ducts, and supporting stroma. Lobules are milk-producing glands, while ducts transport milk to the nipple. These epithelial structures are embedded within a stromal environment made up of adipose tissue, fibroblasts, blood vessels, and immune cells.

Most breast cancers originate from the epithelial cells lining the ducts or lobules. This explains why the majority of cases are classified as ductal or lobular carcinomas. Under normal conditions, epithelial cell proliferation is tightly regulated by hormonal signals and cell–cell interactions. When this regulation is disrupted, cells may acquire abnormal growth advantages that initiate tumor formation.

Early neoplastic changes often begin as in situ lesions, where abnormal cells remain confined within ducts or lobules. As additional genetic and cellular alterations accumulate, these cells can breach the basement membrane, leading to invasive breast cancer. The surrounding stromal cells and extracellular matrix play a crucial role in supporting or restraining this progression.

Understanding breast anatomy and the cellular origin of tumors provides a foundation for interpreting histological classifications, imaging findings, and therapeutic strategies discussed in later sections.

Diagram illustrating breast anatomy and the cellular progression of breast cancer, showing terminal duct lobular units (TDLUs), mammary ducts, surrounding stroma, luminal and myoepithelial cells, and the progression from normal breast epithelium through hyperplasia and carcinoma in situ to invasive carcinoma.
Breast anatomy and the cellular origin of breast cancer. (A) Structural organization of the breast, highlighting terminal duct lobular units (TDLUs), collecting ducts, and surrounding stromal tissue. Magnified views illustrate the cellular composition of mammary ducts, including luminal cells, myoepithelial cells, and the basement membrane. (B) Stages of breast cancer development, from normal breast epithelium through epithelial hyperplasia and carcinoma in situ to invasive carcinoma, characterized by tumor cell proliferation and invasion beyond the basement membrane.
Adapted from: Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023 Apr 13;186(8):1708-1728. doi: 10.1016/j.cell.2023.01.040.

2. Molecular and Cellular Basis of Breast Cancer

Breast cancer development is driven by a complex interplay of genetic alterations, hormonal signaling, and cellular interactions within the tumor microenvironment. These molecular and cellular events disrupt normal growth control mechanisms, allowing cells to proliferate, survive, and invade surrounding tissues.

2.1 Genetic and Epigenetic Alterations

At the core of breast carcinogenesis are accumulated genetic changes that affect key regulators of the cell cycle, apoptosis, and DNA repair. These alterations may be somatic, arising during a person’s lifetime, or hereditary, inherited through germline mutations.

Common molecular events include:

In addition to DNA mutations, epigenetic modifications such as DNA methylation and histone modification alter gene expression without changing the DNA sequence. These changes can silence tumor suppressor genes or activate oncogenic pathways, further contributing to tumor progression.

2.2 Hormonal Regulation and Carcinogenesis

Breast tissue is highly sensitive to hormonal signals, particularly estrogen and progesterone, which regulate normal development and cyclical proliferation. In many breast cancers, these hormonal pathways are hijacked to support malignant growth.

Key features include:

  • Overactivation of estrogen receptor–mediated transcription
  • Hormone-dependent proliferation of cancer cells
  • Loss of normal feedback mechanisms controlling hormone signaling

Hormone receptor–positive tumors rely on these pathways for survival, making hormonal signaling a central driver of tumor growth and a major therapeutic target.

2.3 Tumor Microenvironment

Breast cancer does not develop in isolation. Tumor cells interact dynamically with their surrounding microenvironment, which includes fibroblasts, immune cells, endothelial cells, and the extracellular matrix.

The tumor microenvironment:

  • Provides growth factors and cytokines that support tumor expansion
  • Facilitates angiogenesis to supply nutrients and oxygen
  • Modulates immune responses, allowing tumor immune evasion

These interactions play a critical role in disease progression, metastasis, and therapeutic resistance.

3. Classification of Breast Cancer

Breast cancer is not a single disease but a group of biologically distinct entities. Classification systems are essential because they provide information about tumor behavior, prognosis, and therapeutic response. Breast cancer is commonly classified using histological, molecular, and clinical criteria.

3.1 Histological Classification

Histological classification is based on the microscopic appearance of tumor cells and their growth pattern within breast tissue.

The two major categories are:

  • Carcinoma in situ
    • Abnormal cells confined within ducts or lobules
    • Basement membrane remains intact
    • Includes ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)
  • Invasive carcinoma
    • Tumor cells breach the basement membrane
    • Capable of invading surrounding tissue and metastasizing

The most common histological types include:

  • Invasive ductal carcinoma (IDC) – the most frequent form
  • Invasive lobular carcinoma (ILC) – characterized by discohesive cells and diffuse growth

Histological grade further evaluates tumor aggressiveness by assessing cellular differentiation, nuclear atypia, and mitotic activity.

3.2 Molecular Classification

Diagram comparing the four main molecular subtypes of breast cancer: Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer. It illustrates their hormone receptor and HER2 status, Ki-67 proliferation index, treatment responses, relapse rates, metastatic patterns, incidence, prognosis, and increasing tumor aggressiveness.
Molecular classification of breast cancer and its clinical implications. The four major molecular subtypes—Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer—differ in estrogen receptor (ER), progesterone receptor (PR), HER2 expression, and Ki-67 proliferation index. These characteristics influence tumor aggressiveness, response to hormone therapy, chemotherapy and anti-HER2 treatment, as well as recurrence and metastatic risk. Luminal A generally has the most favorable prognosis, whereas triple-negative breast cancer is associated with more aggressive behavior and a poorer prognosis. Overall, tumor aggressiveness tends to increase toward the triple-negative subtype.
Source: Llaguno-Munive M, Vazquez-Lopez MI, Garcia-Lopez P. Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer. Int J Mol Sci. 2024 Oct 5;25(19):10712. doi: 10.3390/ijms251910712.

Molecular classification is based on gene expression profiles and immunohistochemical markers. This system reflects the biological diversity of breast cancer and has major clinical significance.

The main molecular subtypes are:

  • Luminal A
    • Hormone receptor–positive
    • Low proliferation rate
    • Generally favorable prognosis
  • Luminal B
    • Hormone receptor–positive
    • Higher proliferative activity
    • More aggressive than Luminal A
  • HER2-enriched
    • Overexpression of HER2
    • High growth potential
    • Historically aggressive, now targetable
  • Triple-negative breast cancer (TNBC)
    • Lacks estrogen, progesterone, and HER2 receptors
    • High heterogeneity and aggressive behavior
    • Limited targeted treatment options

This classification highlights how molecular features drive tumor biology and treatment decisions.

3.3 Clinical Relevance of Classification

Breast cancer classification directly influences clinical management by:

  • Guiding therapy selection
  • Predicting disease progression
  • Estimating recurrence risk
  • Informing patient prognosis

For example, hormone receptor–positive tumors are candidates for endocrine therapy, while HER2-positive tumors benefit from targeted approaches. In contrast, triple-negative tumors often require aggressive systemic treatment due to limited molecular targets.

By integrating histological and molecular classification systems, clinicians and researchers can better understand tumor heterogeneity and design personalized therapeutic strategies.

4. Epidemiology and Risk Factors of Breast Cancer

4.1 Epidemiology

Bar chart showing global age-standardized cancer incidence and mortality rates per 100,000 population in 2024. Breast cancer ranks first in incidence, followed by prostate and lung cancers, while lung cancer has the highest mortality rate. Data from IARC GLOBOCAN 2024.
Age-standardized incidence and mortality rates of the 15 leading cancer sites worldwide in 2024, highlighting breast cancer as the most frequently diagnosed cancer.

Breast cancer remains one of the most significant global public health challenges. According to the International Agency for Research on Cancer (IARC), the GLOBOCAN 2024 estimates identify breast cancer as the leading cancer site in terms of incidence worldwide, affecting predominantly women.

Approximately 2.43 million new cases of breast cancer and 694,000 deaths were recorded worldwide in 2024.

According to the 2024 global data, breast cancer has an age-standardized incidence rate (ASR) of approximately 47 cases per 100,000 population and an age-standardized mortality rate of approximately 13 deaths per 100,000 population (both sexes combined). These rates are adjusted for differences in population age structure, allowing comparisons between populations.

Among the 15 leading cancer sites presented in the IARC comparison, breast cancer shows the highest incidence rate, exceeding prostate and lung cancers. However, its mortality rate is lower than that of lung cancer, which has the highest mortality rate in the comparison. This difference highlights the importance of early detection and advances in breast cancer management.

Breast cancer predominantly affects women, although it can also occur in men. Its global burden varies considerably across regions, reflecting differences in risk factors, population characteristics, screening practices, early diagnosis, and access to effective treatment.

4.2 Non-Modifiable Risk Factors

Certain factors increase breast cancer risk regardless of lifestyle or behavior.

Key non-modifiable risk factors include:

  • Sex and age: Risk increases with advancing age and is significantly higher in women
  • Genetic predisposition: Inherited mutations in high-risk genes markedly elevate lifetime risk
  • Family history: Having first-degree relatives with breast cancer increases susceptibility
  • Early menarche and late menopause: Prolonged lifetime exposure to estrogen

These factors primarily influence risk by increasing cumulative hormonal exposure or by impairing genomic stability.

4.3 Modifiable Risk Factors

Several lifestyle and environmental factors contribute to breast cancer risk and represent potential targets for prevention.

Important modifiable risk factors include:

  • Hormonal exposure: Prolonged use of hormone replacement therapy
  • Reproductive factors: Late age at first full-term pregnancy or nulliparity
  • Obesity: Particularly after menopause, due to increased estrogen production by adipose tissue
  • Physical inactivity: Reduced metabolic and hormonal regulation
  • Alcohol consumption: Associated with increased estrogen levels and DNA damage

Modifying these factors can significantly reduce breast cancer risk at the population level.

4.4 Environmental and Biological Contributors

Beyond classical risk factors, additional biological processes influence breast cancer development:

  • Chronic inflammation
  • Oxidative stress
  • Disruption of normal endocrine signaling

These contributors can promote DNA damage, alter gene expression, and support malignant transformation.

5. Breast Cancer Progression and Metastasis

Breast cancer progression is a multistep biological process through which localized tumor cells acquire increasingly aggressive characteristics. These changes enable cancer cells to invade surrounding tissues, enter circulation, and colonize distant organs, ultimately leading to metastasis—the primary cause of breast cancer–related mortality.

5.1 Local Tumor Growth and Invasion

Early breast cancer begins as a localized lesion confined to ducts or lobules. As genetic and epigenetic alterations accumulate, tumor cells gain the ability to:

  • Proliferate independently of normal growth signals
  • Degrade the basement membrane
  • Invade adjacent stromal tissue

This transition from in situ to invasive carcinoma marks a critical step in disease progression.

5.2 Epithelial–Mesenchymal Transition (EMT)

A key mechanism facilitating invasion and dissemination is epithelial–mesenchymal transition (EMT). During EMT, epithelial cancer cells undergo phenotypic changes that enhance motility and invasiveness.

Characteristics of EMT include:

  • Loss of cell–cell adhesion
  • Increased migratory capacity
  • Enhanced resistance to apoptosis

EMT also contributes to therapeutic resistance and the acquisition of stem cell–like properties.

5.3 Intravasation and Systemic Dissemination

Invasive breast cancer cells can enter the lymphatic or blood circulation through a process known as intravasation. Once in circulation, these cells must survive mechanical stress and immune surveillance.

Dissemination occurs via:

  • Lymphatic spread, often leading to regional lymph node involvement
  • Hematogenous spread, enabling distant organ colonization

5.4 Metastatic Colonization

Only a small fraction of circulating tumor cells successfully establish metastases. This requires adaptation to the microenvironment of distant organs.

Common metastatic sites in breast cancer include:

  • Bone
  • Lung
  • Liver
  • Brain

The ability of breast cancer cells to colonize specific organs reflects complex interactions between tumor cell properties and organ-specific niches.

6. Diagnosis and Screening of Breast Cancer

Early and accurate detection of breast cancer is critical for improving patient outcomes. Diagnostic and screening strategies combine imaging techniques, histopathological evaluation, and molecular testing to identify disease, define tumor characteristics, and guide treatment decisions.

6.1 Screening Methods

Screening aims to detect breast cancer at an early, asymptomatic stage.

The main screening modalities include:

  • Mammography: The primary screening tool; effective in detecting microcalcifications and early lesions
  • Ultrasound: Useful as an adjunct, especially in dense breast tissue
  • Magnetic resonance imaging (MRI): High sensitivity; recommended for high-risk individuals

Regular screening significantly increases the likelihood of early diagnosis and successful treatment.

6.2 Diagnostic Evaluation

When abnormalities are detected, further diagnostic procedures are required to confirm malignancy.

Key diagnostic steps include:

  • Clinical examination: Assessment of breast masses and lymph nodes
  • Biopsy: Core needle or surgical biopsy to obtain tissue samples
  • Histopathological analysis: Evaluation of tumor type, grade, and invasiveness

Histology remains the gold standard for definitive breast cancer diagnosis.

6.3 Biomarker and Molecular Testing

Modern breast cancer diagnosis extends beyond morphology to include biomarker assessment.

Essential biomarkers include:

  • Estrogen receptor (ER)
  • Progesterone receptor (PR)
  • HER2 expression

These markers are assessed by immunohistochemistry and guide classification, prognosis, and therapy selection. Additional molecular tests can further refine risk stratification and treatment planning.

Diagnosis and screening represent a critical interface between cancer biology and clinical practice, enabling early intervention and personalized management strategies.

7. Staging and Prognostic Factors in Breast Cancer

Staging and prognostic assessment are essential for determining disease extent, treatment strategy, and expected clinical outcome in breast cancer. These evaluations integrate anatomical, pathological, and biological information to provide a comprehensive view of tumor behavior.

7.1 TNM Staging System

Breast cancer staging is primarily based on the TNM system, which evaluates:

  • T (Tumor size): Extent of the primary tumor within the breast
  • N (Nodal involvement): Presence and number of affected regional lymph nodes
  • M (Metastasis): Evidence of distant metastatic spread

Based on TNM parameters, breast cancer is classified into stages ranging from Stage 0 (in situ disease) to Stage IV (metastatic disease). Higher stages reflect greater tumor burden and worse prognosis.

7.2 Pathological and Biological Prognostic Factors

Beyond anatomical staging, several tumor-specific characteristics influence disease outcome.

Key prognostic factors include:

  • Tumor grade: Reflects cellular differentiation and proliferative activity
  • Hormone receptor status: ER and PR positivity are associated with better outcomes
  • HER2 expression: Indicates aggressive behavior but predicts response to targeted therapy
  • Proliferation markers: High proliferative index correlates with poorer prognosis

These factors help refine risk stratification and guide adjuvant therapy decisions.

7.3 Clinical Importance of Prognostic Assessment

Accurate staging and prognostic evaluation:

  • Inform treatment intensity
  • Predict recurrence risk
  • Estimate overall and disease-free survival
  • Support personalized therapeutic planning

By integrating staging with molecular and pathological features, clinicians can tailor management strategies to individual patient profiles.

Staging and prognostic factors form the foundation for clinical decision-making in breast cancer and directly influence therapeutic approaches discussed in the following section.

8. Therapeutic Strategies in Breast Cancer

Breast cancer treatment is multimodal and depends on tumor stage, molecular subtype, and patient-specific factors. The goal of therapy is to eliminate the primary tumor, prevent recurrence, and reduce metastatic risk while preserving quality of life.

8.1 Surgical Treatment

Surgery is the cornerstone of treatment for localized breast cancer and aims to remove the tumor with clear margins.

Main surgical approaches include:

  • Breast-conserving surgery (lumpectomy): Removal of the tumor with surrounding tissue
  • Mastectomy: Complete removal of breast tissue
  • Sentinel lymph node biopsy: Assessment of nodal involvement

Surgical choice depends on tumor size, location, and patient preference.

8.2 Radiotherapy

Radiotherapy is commonly used after surgery to eliminate residual cancer cells.

Key features include:

  • Local control of disease
  • Reduction of recurrence risk
  • Use as adjuvant or, in selected cases, neoadjuvant therapy

Radiotherapy is especially important following breast-conserving surgery.

8.3 Systemic Therapies

Systemic treatments target cancer cells throughout the body and are essential for preventing distant relapse.

Major systemic approaches include:

  • Chemotherapy: Targets rapidly dividing cells
  • Hormone therapy: Blocks estrogen or progesterone signaling in receptor-positive tumors
  • Targeted therapy: Inhibits specific molecular drivers such as HER2
  • Immunotherapy: Enhances immune-mediated tumor destruction in selected cases

The choice of systemic therapy is guided by tumor biology and prognostic factors.

8.4 Personalized and Precision Medicine

Advances in breast cancer biology have enabled personalized treatment strategies.

Precision medicine:

  • Uses biomarkers to guide therapy selection
  • Minimizes overtreatment
  • Improves therapeutic efficacy

Conclusion

Breast cancer is a biologically diverse disease shaped by complex interactions between genetic alterations, hormonal signaling, and the tumor microenvironment. Advances in classification, diagnosis, and treatment have transformed clinical management, enabling more precise and effective therapeutic strategies. Continued integration of cancer biology with early detection and personalized medicine remains essential for improving patient outcomes and reducing the global burden of breast cancer.

References and Further Reading

  1. Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022 Feb 2;83(2):1-7. doi: 10.12968/hmed.2021.0459.
  2. Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025 Feb 19;10(1):49. doi: 10.1038/s41392-024-02108-4.
  3. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020 Jul;84:106535. doi: 10.1016/j.intimp.2020.106535.
  4. Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023 Apr 13;186(8):1708-1728. doi: 10.1016/j.cell.2023.01.040.
  5. Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026 Jul-Aug;76(4):e70090. doi: 10.3322/caac.70090.
  6. Breast cancer, World Health Organization: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
  7. Llaguno-Munive M, Vazquez-Lopez MI, Garcia-Lopez P. Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer. Int J Mol Sci. 2024 Oct 5;25(19):10712. doi: 10.3390/ijms251910712.
- Advertisement -
Mohamed NAJID
Mohamed NAJIDhttps://cancerbiologyresearch.com/about-us/
Mohamed Najid is a PhD student in Cancer Cell Biology with a Master’s degree in Cancer Biology. His research focuses on circulating tumor cells (CTCs) in bladder cancer and their role as emerging diagnostic biomarkers.He creates clear, science-based content to help readers understand medical tests, cancer biology, and everyday health topics—without the confusion.ResearchGate: https://www.researchgate.net/profile/Mohamed-Najid-2 ORCID: https://orcid.org/0009-0002-7491-3366
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisment -

Related Articles